Top Markets
Coin of the day
ProMIS Neurosciences, Inc. ProMIS Neurosciences, Inc.

ProMIS Neurosciences, Inc.

PMN
株式のランク #26786
Based in Toronto, Canada, ProMIS Neurosciences, Inc. focuses on developing... Based in Toronto, Canada, ProMIS Neurosciences, Inc. focuses on developing precise medical solutions for severe neurodegenerative disorders, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company employs a unique discovery platform, which incorporates proprietary algorithms like ProMIS and Collective Coordinates, to identify novel, disease-specific targets, known as epitopes, located on the surface of misfolded proteins. The firm's primary product candidates include PMN310, a monoclonal antibody designed to combat toxic oligomers associated with Alzheimer's disease. Another candidate, PMN267, aims to target proteins such as superoxide dismutase 1 and TAR-DNA binding protein 43 relevant to ALS, as well as alpha-synuclein implicated in Parkinson's disease and Lewy body dementia. Additionally, PMN442 is a monoclonal antibody engineered to address toxic alpha-synuclein oligomers and seeding fibrils linked to MSA. Originally established in 2004, the company was known as Amorfix Life Sciences Ltd. before officially adopting the name ProMIS Neurosciences, Inc. in July 2015.
株価
$4.40
最終同期: 2023-07-21
時価総額
$37.78M
変化(1日)
-7.03%
変化(1年)
0.00%
CA
取引 ProMIS Neurosciences, Inc. (PMN)

カテゴリー

ProMIS Neurosciences, Inc.(PMN)の配当利回りの履歴
ProMIS Neurosciences, Inc.(銘柄コード: PMN)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
ProMIS Neurosciences, Inc.(PMN)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)